Evidence
Int Clin Psychopharmacol. 2024 Feb 13. doi: 10.1097/YIC.0000000000000538. Online ahead of print.
ABSTRACT
The risk of metabolic syndrome (MetS) has been attributed to antipsychotic use in psychiatric patients. To date, there is limited data on the relationship between antipsychotic polypharmacy and MetS in patients with schizophrenia, schizoaffective disorder and bipolar disorder. Therefore, we aimed to investigate the rate of MetS in patients with these disorders receiving antipsychotic monotherapy and polypharmacy. We conducted a cross-sectional study on patients seen between January 2017 and December 2020, collecting data on the class, type, route of administration and number of antipsychotics received. We used the American Association of Clinical Endocrinology criteria to diagnose MetS. We included 833 subjects of whom 573 (68.8%) received antipsychotic monotherapy and 260 (31.2%) received polypharmacy. Overall, 28.6% (N = 238) had MetS with no statistical difference between the two groups. Diastolic blood pressure and receiving olanzapine were significant predictors for developing MetS. In conclusion, our study found no significant difference in the rate of MetS between antipsychotic monotherapy and polypharmacy. A number of variables were significant predictors for MetS. Our findings were consistent with other studies and warrant the need for careful choice of antipsychotics and regular screening and management of abnormal metabolic parameters.
PMID:38381917 | DOI:10.1097/YIC.0000000000000538
Add to Google Keep
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders
🌐 90 Days
VR Related Evidence Matrix
- Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders
- Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders
- Association of cytokines levels, psychopathology and cognition among CR-TRS patients with metabolic syndrome
- Genetic predisposition and antipsychotic treatment effect on metabolic syndrome in schizophrenia: a ten-year follow-up study using the Estonian Biobank
- Genetic predisposition and antipsychotic treatment effect on metabolic syndrome in schizophrenia: a ten-year follow-up study using the Estonian Biobank
- Gender Differences in the Prevalence and Clinical Correlates of Metabolic Syndrome in First-Episode and Drug-Naïve Patients With Major Depressive Disorder
- Inpatient antipsychotic medication switching and rehospitalization risk among patients with schizophrenia-spectrum disorders
- Inpatient antipsychotic medication switching and rehospitalization risk among patients with schizophrenia-spectrum disorders
- Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review
- Antipsychotic prescribing and drug-related readmissions in multimorbid older inpatients: a post-hoc analysis of the OPERAM population
- The Association Between Mood Stabilizers, Sleep Quality, and Functioning in Patients With Remitted Bipolar Disorder
- Schizophrenia and schizoaffective disorder: Length of stay and associated factors
- Schizophrenia and schizoaffective disorder: Length of stay and associated factors
- Cognitive Outcomes in Nonacute Patients With Schizophrenia Treated With Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics
- Metabolic Syndrome in people treated with Antipsychotics (RISKMet): A multimethod study protocol investigating genetic, behavioural, and environmental risk factors
- Polypharmacy and associated factors in South Korean elderly patients with dementia: An analysis using National Health Insurance claims data
- Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication
- Psychotropic Medication Use and Polypharmacy Among Children and Adolescents Initiating Intensive Behavioral Therapy for Severe Challenging Behavior
- Psychotropic Medication Use and Polypharmacy Among Children and Adolescents Initiating Intensive Behavioral Therapy for Severe Challenging Behavior
- Racial disparities with PRN medication usage in inpatient psychiatric treatment
- Visceral and subcutaneous abdominal fat is associated with non-alcoholic fatty liver disease while augmenting Metabolic Syndrome's effect on non-alcoholic fatty liver disease: A cross-sectional study of NHANES 2017-2018
- The advent of RNA-based therapeutics for metabolic syndrome and associated conditions: a comprehensive review of the literature
- The relationship between clinical presentation and the nature of care in adults with intellectual disability and epilepsy - national comparative cohort study
- The relationship between clinical presentation and the nature of care in adults with intellectual disability and epilepsy - national comparative cohort study
- Metabolic syndrome: a population-based study of prevalence and risk factors
- Pediatric Extrapolation Approach for U.S. Food and Drug Administration Approval of Brexpiprazole in Patients Aged 13 to 17 Years with Schizophrenia
- Stimulant Patterns, Alone or with Other Psychotropic Classes, in Medicaid-Insured Youth Continuously Enrolled for 3-8 Years
- Prospective, comparative, pilot study of maintenance treatment in comorbid bipolar disorders with post-traumatic stress disorder
- Medical comorbidities in bipolar disorder (BIPCOM): clinical validation of risk factors and biomarkers to improve prevention and treatment. Study protocol
- The overlap across psychotic disorders: A functional network connectivity analysis
- Recent updates on treatment patterns in patients with treated attention-deficit/hyperactivity disorders from a nationwide real-world database in South Korea
- Antipsychotic prescribing patterns in children and adolescents attending Australian general practice in 2011 and 2017
- Evaluation of Met and Unmet Needs in Patients with Severe Psychiatric Disorders and its Relation to the Quality of Life: A Cross-Sectional Study
- Clinical experiences of guided tapering of antipsychotics for patients with schizophrenia- a case series
- Efficacy and Safety of Valbenazine in Japanese Patients With Tardive Dyskinesia and Schizophrenia/Schizoaffective Disorder or Bipolar Disorder/Depressive Disorder: Primary Results and Post Hoc Analyses of the J-KINECT Study
- Use of antipsychotic medication, benzodiazepines, and psychiatric hospitalization in cannabis-related versus cannabis-unrelated schizophrenia - a nationwide, register-based cohort study
- Mirtazapine Monotherapy for Antipsychotics-refractory Psychosis in a Patient with Very-late-onset Schizophrenia-like Psychosis: A Case Report
- Association between endocrine-disrupting chemical mixtures and non-alcoholic fatty liver disease with metabolic syndrome as a mediator among adults: A population-based study in Korea
- Prescriptions for Antipsychotics: Youth with Intellectual/Developmental Disabilities Compared to Youth without Intellectual/Developmental Disabilities
- Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022
- Withdrawal syndrome after antipsychotics discontinuation: an analysis of the WHO database of spontaneous reports (Vigibase) between 2000 and 2022
- Assessment of Monitoring and Management Practices of Antipsychotic-Induced Hyperprolactinemia at a Medical City in Riyadh, Saudi Arabia: A Retrospective Cohort Study
- Antipsychotic prescribing: national findings of children and adolescents attending mental health services in Ireland
- Enlarged pituitary gland volume: a possible state rather than trait marker of psychotic disorders
- Clinical Characteristics of Asymptomatic Thromboembolism in Psychiatric Inpatients: A Retrospective Study
- D-serine and D-amino acid oxidase levels in patients with schizophrenia spectrum disorders in the first episode and 6-month follow-up
- Lipid and Glucose Profile across Different Mental Disorders
- The contribution of first-episode illness characteristics and cumulative antipsychotic usage to progressive structural brain changes over a long-term follow-up in schizophrenia
- Distinct neuroanatomic subtypes in antipsychotic-treated patients with schizophrenia classified by the predefined classification in a never-treated sample
- Clinical implementation of preemptive pharmacogenomics in psychiatry
- Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT2A receptor
- The psychopathology among the offspring of schizophrenia and bipolar I disorder patients in an Egyptian sample: A comparative study
- CaMKII activity and metabolic imbalance-related neurological diseases: Focus on vascular dysfunction, synaptic plasticity, amyloid beta accumulation, and lipid metabolism
- Psychotropic Medication Prescriptions for Home-Based Palliative Care Oncology Patients
- Management of antipsychotics in primary care: Insights from healthcare professionals and policy makers in the United Kingdom
- Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland
- Rapid Metabolism Underlying Subtherapeutic Serum Levels of Atypical Antipsychotics Preceding Clozapine Treatment: A Retrospective Analysis of Real-World Data
- Assessing regional intracortical myelination in schizophrenia spectrum and bipolar disorders using the optimized T1w/T2w-ratio
- Long-term persistence of the risk of agranulocytosis with clozapine compared with other antipsychotics: a nationwide cohort and case-control study in Finland
- Sex Differences Between Female and Male Individuals in Antipsychotic Efficacy and Adverse Effects in the Treatment of Schizophrenia
- Clozapine Use Among People With Psychotic Disorders Who Experience Specific Indications for Clozapine
- Clozapine Use Among People With Psychotic Disorders Who Experience Specific Indications for Clozapine
- Association between prenatal antipsychotic exposure and the risk of attention-deficit/hyperactivity disorder and autism spectrum disorder: a systematic review and meta-analysis
- Ketogenic Diet Intervention on Metabolic and Psychiatric Health in Bipolar and Schizophrenia: A Pilot Trial
Evidence Blueprint
Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders
🌐 365 Days
VR Related Evidence Matrix
- Metabolic syndrome and its relation to antipsychotic polypharmacy in schizophrenia, schizoaffective and bipolar disorders
- Prevalence and risk factors for metabolic syndrome in schizophrenia, schizoaffective, and bipolar disorder
- Real-World Evidence of Antipsychotic Monotherapy Versus Polypharmacy in the Treatment of Schizophrenia Spectrum Disorders
- Polygenic liability for antipsychotic dosage and polypharmacy - a real-world registry and biobank study
- Antipsychotic Medication and Risk of Metabolic Disorders in People With Schizophrenia: A Longitudinal Study Using the UK Clinical Practice Research Datalink
- Hypertension and psychosis
- Association of cytokines levels, psychopathology and cognition among CR-TRS patients with metabolic syndrome
- Schizophrenia patients discharged on antipsychotic polypharmacy from a public psychiatric hospital in Taiwan, 2006-2021
- Prevalence and factors associated with metabolic syndrome in first hospitalization for major depression disorder patients
- Nationwide study on antipsychotic polypharmacy among forensic psychiatric patients
- Genetic predisposition and antipsychotic treatment effect on metabolic syndrome in schizophrenia: a ten-year follow-up study using the Estonian Biobank
- Genetic predisposition and antipsychotic treatment effect on metabolic syndrome in schizophrenia: a ten-year follow-up study using the Estonian Biobank
- Clinical correlates and thyroid hormones of metabolic syndrome in first-episode and drug-naïve major depressive disorder outpatients with and without hyperglycemia: a comprehensive cross-sectional study
- Therapeutic Drug Level Monitoring of Antipsychotics at an Inpatient Psychiatric Hospital
- Gender Differences in the Prevalence and Clinical Correlates of Metabolic Syndrome in First-Episode and Drug-Naïve Patients With Major Depressive Disorder
- Incidence and predictors of metabolic syndrome onset in individuals with bipolar disorders: A longitudinal study from the FACE-BD cohort
- Inpatient antipsychotic medication switching and rehospitalization risk among patients with schizophrenia-spectrum disorders
- Inpatient antipsychotic medication switching and rehospitalization risk among patients with schizophrenia-spectrum disorders
- Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review
- Efficacy of Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics in Preventing Psychiatric Rehospitalizations
- Metabolic syndrome in patients with obsessive-compulsive disorder
- Association of metabolic syndrome components and NAFLD with quality of life: Insights from a cross-sectional study
- Risk factors for abnormal glucose metabolism during antipsychotic treatment: A prospective cohort study
- Treatment adherence in forensic patients with schizophrenia spectrum disorders discharged on long-acting injectable antipsychotics: a comparative 3-year mirror-image study
- Antipsychotic prescribing and drug-related readmissions in multimorbid older inpatients: a post-hoc analysis of the OPERAM population
- Effects of Metabolic Syndrome and Sex on Stress Coping Strategies in Individuals with Depressive Disorder
- Change of prescription for patients with schizophrenia or major depressive disorder during admission: real-world prescribing surveys from the effectiveness of guidelines for dissemination and education psychiatric treatment project
- Metabolic effects of atypical antipsychotics: Molecular targets
- A multicenter, single-arm, open-label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder
- What clinical analysis of antipsychotic-induced catatonia and neuroleptic malignant syndrome tells us about the links between these two syndromes: A systematic review
- Genetic evidence for the causal relations between metabolic syndrome and psychiatric disorders: a Mendelian randomization study
- Breast cancer risks following antipsychotic use in women with bipolar disorder versus schizophrenia: A territory-wide nested case-control study spanning two decades
- The Association Between Mood Stabilizers, Sleep Quality, and Functioning in Patients With Remitted Bipolar Disorder
- Microglial Ffar4 deficiency promotes cognitive impairment in the context of metabolic syndrome
- Schizophrenia and schizoaffective disorder: Length of stay and associated factors
- Schizophrenia and schizoaffective disorder: Length of stay and associated factors
- Cognitive Outcomes in Nonacute Patients With Schizophrenia Treated With Long-Acting Injectable Antipsychotics Versus Oral Antipsychotics
- Metabolic Syndrome in people treated with Antipsychotics (RISKMet): A multimethod study protocol investigating genetic, behavioural, and environmental risk factors
- Association between metabolic syndrome and stroke: a population based cohort study
- A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia
- The Impact of Clozapine Delay on Clinical Outcomes in Schizophrenia
- Gender differences in prevalence and associated factors of metabolic syndrome in first-treatment and drug-naïve schizophrenia patients
- A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review
- Prevalence and clinical correlates of thyroid dysfunction in first-episode and drug-naïve major depressive disorder patients with metabolic syndrome
- A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder
- Prevalence and Correlates Of Sexual Dysfunction Among Patients With Schizophrenia Spectrum Disorder on Antipsyhotic Medications in Maiduguri, Northeastern Nigeria
- The link between Alzheimer disease and metabolic syndrome: A mutual relationship and long rigorous investigation
- No gender differences in the pharmacological emergency treatment of schizophrenia: results of a 21-year observation
- Antipsychotic medication non-adherence and factors associated among patients with schizophrenia in eastern Ethiopia
- The Association between Peripheral Inflammation, Brain Glutamate and Antipsychotic Response in Schizophrenia: data from the STRATA collaboration
- Polypharmacy and associated factors in South Korean elderly patients with dementia: An analysis using National Health Insurance claims data
- Evaluating lumateperone for its use in treating depressive episodes associated with bipolar I or II disorder in adults
- Endocannabinoid system alterations in schizophrenia: association with cannabis use and antipsychotic medication
- Management practice and discharge outcome of patients with psychiatric disorder admitted to psychiatry wards of selected specialized settings in Ethiopia
- Psychotropic Medication Use and Polypharmacy Among Children and Adolescents Initiating Intensive Behavioral Therapy for Severe Challenging Behavior
- Psychotropic Medication Use and Polypharmacy Among Children and Adolescents Initiating Intensive Behavioral Therapy for Severe Challenging Behavior
- Temporal trends in antipsychotic prescriptions for pediatric patients using an administrative hospital database in Japan: a retrospective study
- Racial disparities with PRN medication usage in inpatient psychiatric treatment
- Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospective cohort study
- Visceral and subcutaneous abdominal fat is associated with non-alcoholic fatty liver disease while augmenting Metabolic Syndrome's effect on non-alcoholic fatty liver disease: A cross-sectional study of NHANES 2017-2018
- The advent of RNA-based therapeutics for metabolic syndrome and associated conditions: a comprehensive review of the literature
- The relationship between clinical presentation and the nature of care in adults with intellectual disability and epilepsy - national comparative cohort study
- The relationship between clinical presentation and the nature of care in adults with intellectual disability and epilepsy - national comparative cohort study
- The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review